title: Topical glaucoma therapy cost in Mexico.
abstract: Glaucoma is an important cause of irreversible blindness that represents a significant economic burden; most direct costs of glaucoma are drug-related. We calculated the annual cost of some of the most commonly prescribed glaucoma medications in Mexico, according to their average wholesale price (AWP) and dose regimen. Annual costs ranged from USD4.97 for Imot 15 ml (timolol 0.5 %; Laboratorios Sophia) to USD675.39 for Alphagan 5 ml (brimonidine 0.2 %; Allergan, Inc.). β-Blockers were the least expensive glaucoma medications (range USD20.44-55.44). Alphagan 5 ml was 250 % more expensive than other selective α(2)-agonists. Of the carbonic anhydrase inhibitors, dorzolamide 2 % was less expensive than brinzolamide 1 % (USD326.91 vs. USD418.96). The annual cost for prostaglandin analogs ranged from USD235.58 for bimatoprost 0.03 % to USD337.78 for latanoprost 0.005 %. Some fixed combinations were less expensive than separate combinations. The average annual cost for all treatments increased by 27.87 ± 10.09 % between 2009 and 2012. Annual glaucoma therapy cost seems to be lower in Mexico than in other countries, due to a lower AWP, especially for some medications made by Mexican laboratories.
authors.affiliation: Asociación Para Evitar la Ceguera en México, I.A.P., Vicente Gacía Torres 46, Barrio San Lucas, CP 04030, Mexico, DF, Mexico.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Lazcano-Gomez
authors.forename: Alejandra
authors.initials: A
authors.lastname: Hernandez-Oteyza
authors.forename: María José
authors.initials: MJ
authors.lastname: Iriarte-Barbosa
authors.forename: Carlos
authors.initials: C
authors.lastname: Hernandez-Garciadiego
mesh_terms: D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000191:economics*; D000959:Antihypertensive Agents / Q000191:economics*; D002257:Carbonic Anhydrase Inhibitors / Q000191:economics*; D016527:Drug Costs; D004359:Drug Therapy, Combination / Q000191:economics; D005901:Glaucoma / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D008800:Mexico; D009883:Ophthalmic Solutions / Q000191:economics; D011453:Prostaglandins / Q000191:economics*
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002257:Carbonic Anhydrase Inhibitors; D009883:Ophthalmic Solutions; D011453:Prostaglandins